In this video, George T. Grossberg, MD , discusses results from the ACCORD-2 study presented at the Alzheimer’s Association International Conference.

The phase three study evaluated AXS-05 (dextromethorphan and bupropion; Axsome) for the treatment of agitation associated with Alzheimer’s disease. AXS-05 met the primary endpoint for efficacy and demonstrated a tolerable safety profile, according to Grossberg, the Henry & Amelia Nasrallah professor and director of the division of geriatric psychiatry in the department of psychiatry and behavioral neuroscience at St. Louis University School of Medicine.

“Because of these findings, I think we feel fairly comfortable and confident to say that AXS-05, dextromethorphan-bupropion, may be, in fact, an appropriate, safe and well-tolerated tre

See Full Page